Company Overview and News

0
Dark clouds gather over Blue Sky following business review

2018-06-12 theage.com.au
Shares in beleaguered, Brisbane-based fund manager Blue Sky Alternative Investments tumbled 15 per cent on Tuesday after it completed a long awaited review of its operations, and revealed it expects a $59.4 million hit to its bottom line for the full year.
BLA

0
Dark clouds gather over Blue Sky following business review

2018-06-12 smh.com.au
Shares in beleaguered, Brisbane-based fund manager Blue Sky Alternative Investments tumbled 15 per cent on Tuesday after it completed a long awaited review of its operations, and revealed it expects a $59.4 million hit to its bottom line for the full year.
BLA

63
ASX advances on positive Trump-Kim summit

2018-06-12 theage.com.au
The Australian sharemarket rose following a "very positive" meeting between US President Donald Trump and North Korean leader Kim Jong-un in Singapore.
BLA PILBF RIO DB BLT RIO CTXAY SNDFY TLSMF HHRBF RTPPF RTNTF SFR RFGPF PLS BHPBF RFG TLM CTX SFRRF BHP RIO CTXAF BBL BHP GNW BHPLF

63
ASX advances on positive Trump-Kim summit

2018-06-12 smh.com.au
The Australian sharemarket rose following a "very positive" meeting between US President Donald Trump and North Korean leader Kim Jong-un in Singapore.
BLA PILBF RIO DB BLT RIO CTXAY SNDFY TLSMF HHRBF RTPPF RTNTF SFR RFGPF PLS BHPBF RFG TLM CTX SFRRF BHP RIO CTXAF BBL BHP GNW BHPLF

0
UPDATE 2-Australia's Blue Sky pulls guidance as shares dive under short-selling attack | Reuters

2018-05-07 reuters
* Blue Sky Shares hit 4-year low, down 78 pct since Glaucus report (Recasts, adds background on Glaucus, Blue Sky statement quotes and stockbroker comment)
BLA

0
Blue Sky Alternative Investments withdraws FY18 outlook, chairman to step down

2018-05-07 reuters
May 7 (Reuters) - Australian investment manager Blue Sky Alternative Investments Ltd withdrew its earnings guidance for the financial year 2018 on Monday and said its chairman would step down once a successor is appointed.
BLA

0
ASX gains for a third straight week

2018-04-20 theage.com.au
A loss on Friday wasn't enough to hinder an otherwise positive performance on the Australian market this week as the index recorded its third consecutive weekly gain.
BLA VLRSY VLRDY VRL WNARF VLRDF WSA

0
ASX gains for a third straight week

2018-04-20 smh.com.au
A loss on Friday wasn't enough to hinder an otherwise positive performance on the Australian market this week as the index recorded its third consecutive weekly gain.
BLA VLRSY VLRDY VRL WNARF VLRDF WSA

1
Thunderclap over Blue Sky disclosure frightens the horses

2018-04-16 theage.com.au
The criticism levelled at troubled Blue Sky Alternative Investments has centred on the overvaluation of its assets and excessive management fees, but it was a profit downgrade on Monday that really frightened the horses.
BLA

1
Thunderclap over Blue Sky disclosure frightens the horses

2018-04-16 smh.com.au
The criticism levelled at troubled Blue Sky Alternative Investments has centred on the overvaluation of its assets and excessive management fees, but it was a profit downgrade on Monday that really frightened the horses.
BLA

9
Brian Gaynor: Short selling not a sure one-way bet

2018-04-06 nzherald.co.nz
Short selling, which involves selling shares first with the aim of buying them back at a lower price, is a well-developed investment strategy.
BLA FBU JBHHY SRHYY FCREY JBH FRCEF SYAAF VRX GXY GALXF FBU SYR

0
Browned off: Fundie that invests in portaloos in US fight

2018-04-05 theage.com.au
The usually shiny, happy people at ASX-listed fund manager Blue Sky Alternative Investments, have had a tough couple of weeks on the local bourse.
BLA

0
Browned off: Fundie that invests in portaloos in US fight

2018-04-05 smh.com.au
The usually shiny, happy people at ASX-listed fund manager Blue Sky Alternative Investments, have had a tough couple of weeks on the local bourse.
BLA

0
Blue Sky shares dip as much as 27% intra-day as trading recommences

2018-04-04 proactiveinvestors.com.au
Blue Sky Alternative Investments Ltd (ASX:BLA) shares recommenced trading this morning after responding to opinions from short-seller Glaucus Research.
BLA

28
ASX tumbles as trade tensions take hold

2018-03-28 theage.com.au
Australian shares fell for the second time in three sessions as another surge in global trade tensions sent investors shying away from equities and as A2 shares fell hard.
BLA RIO RIO MS.PRE MS.PRF MS.PRG MS.PRA RTPPF MS.PRI MS.PRK RIO RTNTF MS

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to ASX:BLA / BLUE SKY ALTERNATIVE INVESTMENTS LIMITED on message board site Silicon Investor.

BB: BlackBerry (fka RIMM: Research in Motion) Blank Check IPOs (SPACS)
Blackhawk Network Holdings, Inc (HAWK) Heinz Blasnik- Views You Can Use
Greenblattu0027s Little Book That Beats The Market BLADEX (BLX)
BLACK BOX STOCKS: Making Sense Out Of Day Trading For The Re URMP BLACK GOLD
Blackstone Group Kathleen Willey blasts Hillaryu0027s u0027dead brokeu0027 claim